A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Researchers are looking for new ways to treat high-risk, localized non-small cell lung cancer (NSCLC) that has been removed with surgery. People with high-risk, localized NSCLC are often treated with surgery. Researchers want to learn if participants can receive 1 or 2 trial treatments to help prevent NSCLC from coming back after surgery. One trial medicine is intismeran (also called V940/mRNA-4157) and the other is subcutaneous pembrolizumab (also called SC pembrolizumab and MK-3475A). Intismeran is designed to help a person's immune system attack their specific cancer. SC pembrolizumab is an immunotherapy treatment which helps the immune system fight cancer. The main purpose of this study is to evaluate whether adjuvant intismeran autogene (V940) in combination with SC pembrolizumab and berahyaluronidase alfa (MK-3475A) or intismeran monotherapy improves disease-free survival (DFS) compared with placebo in participants with completely resected high-risk Stage I NSCLC.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Rak płuca (NSCLC) wykryty we wczesnym stadium (Etap I) usunięty chirurgicznie.
- •Rak płuca o podwyższonym ryzyku nawrotu po operacji.
- •Brak wcześniejszego leczenia raka poza operacją (np. chemioterapii, radioterapii).
- •Dostarczenie próbki tkanki nowotworowej i próbki krwi z ostatniej operacji.
- •Osoby zakażone wirusem HIV muszą mieć dobrze kontrolowane zakażenie przyjmowanymi lekami.
- •Osoby zakażone wirusem zapalenia wątroby typu B (WZW B) muszą być leczone i mieć niewykrywalną ilość wirusa we krwi.
- •Osoby po przebyciu zakażenia wirusem zapalenia wątroby typu C (WZW C) muszą mieć niewykrywalną ilość wirusa we krwi.
✗ Disqualifies
- •Inny rodzaj raka płuca (np. rak drobnokomórkowy) lub niejednoznaczny typ guza.
- •Znaczące problemy z sercem w ciągu ostatniego roku przed badaniem (np. przebyty zawał, niewydolność serca, poważne choroby zastawek).
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 1, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (104)
UC Davis Comprehensive Cancer Center ( Site 3204)
Sacramento, United States
University of Colorado Cancer Center ( Site 3268)
Aurora, United States
Smilow Cancer Center at Yale-New Haven ( Site 3253)
New Haven, United States
Illinois Cancer Care ( Site 7000)
Peoria, United States
Washington University School of Medicine ( Site 3279)
St Louis, United States
Billings Clinic ( Site 3255)
Billings, United States
NHO Revive Research Institute, LLC ( Site 3218)
Lincoln, United States
Renown Regional Medical Center-Renown Health Medical Oncology ( Site 3207)
Reno, United States
New York Oncology Hematology, P.C. ( Site 9000)
Albany, United States
White Plains Hospital ( Site 3213)
White Plains, United States
Charles George VA Medical Center ( Site 3233)
Asheville, United States
UNC Lineberger Comprehensive Cancer Center ( Site 3250)
Chapel Hill, United States
WakeMed Raleigh Campus ( Site 3214)
Raleigh, United States
Sanford Fargo Medical Center ( Site 3236)
Fargo, United States
Altru Health System ( Site 3254)
Grand Forks, United States
Perelman Center for Advanced Medicine ( Site 3205)
Philadelphia, United States
Sanford Cancer Center ( Site 3266)
Sioux Falls, United States
Avera Cancer Institute ( Site 3209)
Sioux Falls, United States
The University of Tennessee Medical Center ( Site 3223)
Knoxville, United States
Hematology Oncology Associates of Fredericksburg ( Site 3275)
Fredericksburg, United States
West Virginia University ( Site 3237)
Morgantown, United States
Royal North Shore Hospital ( Site 0502)
St Leonards, Australia
Princess Alexandra Hospital ( Site 0503)
Brisbane, Australia
One Clinical Research ( Site 0501)
Nedlands, Australia
Hospital Sírio Libanês ( Site 3611)
São Paulo, Brazil
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2506)
Hamilton, Canada
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2503)
Kingston, Canada
Centre Hospitalier de l'Université de Montréal ( Site 2501)
Montreal, Canada
Clínica MEDS La Dehesa ( Site 3708)
Lo Barnechea, Chile
Centro de Oncología de Precisión ( Site 3706)
Santiago, Chile
Bradfordhill-Clinical Area ( Site 3700)
Santiago, Chile
ONCOCENTRO APYS-ACEREY ( Site 3704)
Viña del Mar, Chile
Bradford Hill Norte ( Site 3705)
Antofagasta, Chile
Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou ( Site 2605)
Rennes, France
Hôpital Foch ( Site 2604)
Suresnes, France
CHU GABRIEL MONTPIED ( Site 2608)
Clermont-Ferrand, France
Thoraxklinik-Heidelberg gGmbH ( Site 2703)
Heidelberg, Germany
Augusta-Kranken-Anstalt ( Site 2702)
Bochum, Germany
Errikos Dunant Hospital Center ( Site 5004)
Athens, Greece
THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 5001)
Athens, Greece
University General Hospital ''Attikon'' - General Hospital of West Attica "H AGIA VARVARA" ( Site 5003)
Athens, Greece
European Interbalkan Medical Center-Oncology Department ( Site 5000)
Thessaloniki, Greece
Pecsi Tudomanyegyetem Klinikai Kozpont ( Site 4401)
Pécs, Hungary
Borsod-Abaúj-Zemplén Vármegyei Központi Kórház És Egyetemi Oktatókórház ( Site 4409)
Miskolc, Hungary
Bacs-Kiskun Varmegyei Oktatokorhaz ( Site 4406)
Kecskemét, Hungary
Nograd Varmegyei Szent Lazar Korhaz ( Site 4410)
Salgótarján, Hungary
Reformatus Pulmonologiai Centrum ( Site 4403)
Törökbálint, Hungary
Országos Onkológiai Intézet ( Site 4405)
Budapest, Hungary
Rambam Health Care Campus ( Site 3303)
Haifa, Israel
Shaare Zedek Medical Center ( Site 3301)
Jerusalem, Israel
Hadassah Medical Center ( Site 3305)
Jerusalem, Israel
Meir medical center ( Site 3306)
Kfar Saba, Israel
Rabin Medical Center ( Site 3304)
Petah Tikva, Israel
Sheba Medical Center ( Site 3302)
Ramat Gan, Israel
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII ( Site 2804)
Bergamo, Italy
Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 2800)
Milan, Italy
Azienda Ospedaliera Universitaria Careggi ( Site 2806)
Florence, Italy
AO Santa Maria della Misericordia ( Site 2809)
Perugia, Italy
Azienda Ospedaliero Universitaria Maggiore della Carità ( Site 2803)
Novara, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 2801)
Roma, Italy
Fukushima Medical University Hospital ( Site 5501)
Fukushima, Japan
Ziekenhuis St. Jansdal ( Site 4800)
Harderwijk, Netherlands
Radboudumc ( Site 4806)
Nijmegen, Netherlands
Nederlands Kanker Instituut Antoni van Leeuwenhoek (NKI AVL) ( Site 4809)
Amsterdam, Netherlands
Elisabeth-TweeSteden Ziekenhuis ( Site 4801)
Tilburg, Netherlands
Isala, locatie Zwolle ( Site 4804)
Zwolle, Netherlands
Frisius Medisch Centrum ( Site 4808)
Leeuwarden, Netherlands
Meander Medisch Centrum ( Site 4802)
Amersfoort, Netherlands
University Medical Center Groningen ( Site 4807)
Groningen, Netherlands
Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 4202)
Poznan, Poland
Instytut Gruzlicy i Chorob Pluc w Warszawie ( Site 4200)
Warsaw, Poland
IP Clinic ( Site 4204)
Lodz, Poland
Wojewodzki Szpital Specjalistyczny im. sw. Rafala w Czerwonej Gorze ( Site 4206)
Chęciny, Poland
National Cancer Center ( Site 5202)
Goyang-si, South Korea
Seoul National University Bundang Hospital ( Site 5200)
Seongnam-si, South Korea
The Catholic University Of Korea St. Vincent's Hospital ( Site 5203)
Suwon, South Korea
Chungbuk National University Hospital ( Site 5201)
Cheongju-si, South Korea
Asan Medical Center ( Site 5205)
Seoul, South Korea
Samsung Medical Center ( Site 5206)
Seoul, South Korea
ICO - Hospital Duran i Reynals ( Site 0301)
L'Hospitalet de Llobregat, Spain
Hospital de Cruces ( Site 0308)
Barakaldo, Spain
Hospital Universitari Vall d'Hebron ( Site 0300)
Barcelona, Spain
Hospital Virgen de la Victoria ( Site 0309)
Málaga, Spain
Hospital Universitario de Badajoz ( Site 0305)
Badajoz, Spain
HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON ( Site 0307)
Madrid, Spain
Hospital Clinico San Carlos ( Site 0303)
Madrid, Spain
Hospital Universitario Virgen Macarena ( Site 0306)
Seville, Spain
Hospital General de Valencia ( Site 0304)
Valencia, Spain
Chang Gung Memorial Hospital at Kaohsiung ( Site 5302)
Kaohsiung City, Taiwan
China Medical University Hospital ( Site 5303)
Taichung, Taiwan
Taichung Veterans General Hospital ( Site 5301)
Taichung, Taiwan
National Cheng Kung University Hospital ( Site 5300)
Tainan, Taiwan
Taipei Medical University Hospital ( Site 5305)
Taipei, Taiwan
Adana Medical Park Seyhan Hastanesi ( Site 4302)
Adana, Turkey (Türkiye)
Hacettepe Universite Hastaneleri-oncology hospital ( Site 4300)
Ankara, Turkey (Türkiye)
Atatürk Göğüs Hastalıkları Ve Göğüs Cerrahisi Eğitim Araştırma Hastanesi ( Site 4309)
Ankara, Turkey (Türkiye)
Ankara Bilkent Sehir Hastanesi ( Site 4306)
Ankara, Turkey (Türkiye)
İstinye Üniversitesi Liv Hospital-Topkapi ( Site 4307)
Istanbul, Turkey (Türkiye)
KARTAL DR. LÜTF KIRDAR ETM VE ARATIRMA HASTANES. ( Site 4308)
Istanbul, Turkey (Türkiye)
Ege Universitesi Hastanesi ( Site 4301)
Izmir, Turkey (Türkiye)
Erciyes Universitesi Tıp Fakultesi Hastaneleri ( Site 4304)
Kayseri, Turkey (Türkiye)
St Bartholomew's Hospital ( Site 0400)
London, United Kingdom
Charing Cross Hospital ( Site 0407)
London, United Kingdom
Singleton Hospital ( Site 0403)
Swansea, United Kingdom
Trial contact
Toll Free Number
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.